Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock on the open market in a transaction that occurred on Friday, June 6th. The shares were purchased at an average price of $9.30 per share, with a total value of $93,000.00. Following the purchase, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $18,483,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Opko Health presently has a consensus rating of “Buy” and a consensus target price of $12.50.

Shares of Opko Health (NYSE:OPK) traded up 2.17% during mid-day trading on Monday, hitting $9.43. The stock had a trading volume of 729,203 shares. Opko Health has a one year low of $6.43 and a one year high of $12.95. The stock’s 50-day moving average is $8. and its 200-day moving average is $8.91. The company’s market cap is $3.902 billion.

Opko Health (NYSE:OPK) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.